Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel
Số trang: 10
Loại file: pdf
Dung lượng: 2.02 MB
Lượt xem: 7
Lượt tải: 0
Xem trước 1 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
In clinical trials, poly (ADP-ribose) polymerase inhibitors (PARPi) versus chemotherapy resulted in significantly improved progression-free survival, manageable adverse event profiles, and favorable patient-reported outcomes (PROs) in patients with human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC) and germline BRCA1/2 mutations (gBRCA1/2mut).
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Clinical trials ADP-ribose Polymerase inhibitors Versus chemotherapy Progression-free survival BRCA1/2 mutationsTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 172 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 142 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 120 0 0 -
12 trang 94 0 0
-
19 trang 74 0 0
-
17 trang 64 0 0
-
9 trang 44 0 0
-
12 trang 38 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 38 0 0